A Chinese biotech company has unveiled a groundbreaking bone adhesive that it claims can repair fractures within minutes sparking both excitement and skepticism online.
The product, known as Bone 02 Bone Adhesive, was developed by Hangzhou Yuannang Biotechnology Co., Ltd. (Yuannang Bio). According to the company, the adhesive is a biodegradable material that works even in wet or blood-filled environments, offering a rapid and efficient solution for bone repair.
Initial skepticism on social media prompted calls for independent verification. However, a review of clinical trial records and investment disclosures has confirmed key aspects of the product’s development and legitimacy.
A report from Artery Network, dated September 11, confirmed that Yuannang Bio recently closed a Series A funding round of nearly 100 million yuan, led by Hetang Venture Capital, with participation from Zheshang Venture Capitaland others.
Zheshang Venture Capital’s involvement is particularly notable it marks their third investmentin the company following earlier rounds in October 2021 and August 2022, with total investments now amounting to tens of millions of yuan.
Yuannang Bio stated that the new funds will be used to further clinical applications and speed up the commercialisation of Bone 02 Bone Adhesive, which it touts as a significant advancement in orthopedic treatment.
About the Author
